Genetic Technologies Ltd (GENE) Stock Price, Forecast & Analysis
USA - NASDAQ:GENE - US37185R4065 - ADR
GENE Key Statistics, Chart & Performance
The current stock price of GENE is 0.765 USD. In the past month the price decreased by -3.89%. In the past year, price decreased by -79.19%.
GENE Latest News, Press Relases and Analysis
GENE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.25 | 222.04B | ||
| DHR | DANAHER CORP | 28.46 | 157.10B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 167.64 | 50.87B | ||
| A | AGILENT TECHNOLOGIES INC | 27.8 | 42.96B | ||
| IQV | IQVIA HOLDINGS INC | 18.99 | 37.55B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.6 | 29.82B | ||
| WAT | WATERS CORP | 30.5 | 23.06B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.73 | 19.69B | ||
| ILMN | ILLUMINA INC | 27.98 | 18.75B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.79 | 16.79B | ||
| TEM | TEMPUS AI INC | N/A | 12.35B | ||
| RVTY | REVVITY INC | 19.65 | 10.93B |
Related stock screener links
About GENE
Company Profile
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Company Info
Genetic Technologies Ltd
60-66 Hanover St, Fitzroy
Melbourne VICTORIA 3065 AU
CEO: Simon Morriss
Employees: 55
Phone: 61394151135
Genetic Technologies Ltd / GENE FAQ
What does Genetic Technologies Ltd do?
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Can you provide the latest stock price for Genetic Technologies Ltd?
The current stock price of GENE is 0.765 USD. The price decreased by -1.92% in the last trading session.
Does GENE stock pay dividends?
GENE does not pay a dividend.
What is the ChartMill technical and fundamental rating of GENE stock?
GENE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for Genetic Technologies Ltd?
Genetic Technologies Ltd (GENE) has a market capitalization of 2.58M USD. This makes GENE a Nano Cap stock.
Can you provide the ownership details for GENE stock?
You can find the ownership structure of Genetic Technologies Ltd (GENE) on the Ownership tab.
GENE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GENE. When comparing the yearly performance of all stocks, GENE is a bad performer in the overall market: 93.77% of all stocks are doing better.
GENE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GENE. GENE has a bad profitability rating. Also its financial health evaluation is rather negative.
GENE Financial Highlights
Over the last trailing twelve months GENE reported a non-GAAP Earnings per Share(EPS) of -2.74. The EPS increased by 19.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.25% | ||
| ROE | -656.53% | ||
| Debt/Equity | 0.36 |